Journal article
Current and future nanoparticle vaccines for COVID-19
MN Vu, HG Kelly, SJ Kent, AK Wheatley
Ebiomedicine | Published : 2021
Abstract
COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vac..
View full abstractGrants
Awarded by Australian Research Council
Funding Acknowledgements
This work was supported by the Australian Research Council (ARC) Centre of Excellence in Convergent Bio-Nano Science and Tech-nology (Project No. CE140100036) . M.N.V. acknowledges the finan-cial support from Monash Graduate Scholarship (MGS) and Monash International Postgraduate Research Scholarship (MIPRS) . SJK and AKW are supported by NHMRC fellowships. Funding sources were not involved in the decision to submit this review for publication or in the writing of this review.